Literature DB >> 7691301

Distinctive increases in HLA-DR+ and CD8+57+ lymphocyte subsets in Wegener's granulomatosis.

M Ikeda1, Y Watanabe, S Kitahara, T Inouye.   

Abstract

Lymphocyte subset abnormalities have been observed in a series of patients diagnosed with Wegener's granulomatosis (WG). Fifteen patients with WG were evaluated for lymphocyte subset abnormalities by two-color immunofluorescence flow cytometry. The WG group showed a decrease in CD4+ cells and an extraordinary increase in HLA-DR+ cells. The average percentages of HLA-DR+ cells of the normal group and WG group were 11.0 +/- 4.0 and 40.5 +/- 13.9% (CD3+HLA-DR+ = 20.3 + 9.4%). Within the CD8 family, CD8+57+, CD8+38+ and CD8+HLA-DR+ cells were markedly elevated. Our findings differ from other series which reported that the lymphocyte subsets in the peripheral blood of patients with WG were normal.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7691301     DOI: 10.1159/000236574

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  3 in total

1.  The CD8+ HLA-DR+ T cells expanded in HIV-1 infection are qualitatively identical to those from healthy controls.

Authors:  Hiromi Imamichi; Richard A Lempicki; Joseph W Adelsberger; Rebecca B Hasley; Alice Rosenberg; Gregg Roby; Catherine A Rehm; Amy Nelson; Sonya Krishnan; Mark Pavlick; Christian J Woods; Michael W Baseler; H Clifford Lane
Journal:  Eur J Immunol       Date:  2012-08-06       Impact factor: 5.532

2.  Activated CD4+ and CD8+ T-cell subsets in Wegener's granulomatosis.

Authors:  M Schlesier; T Kaspar; J Gutfleisch; G Wolff-Vorbeck; H H Peter
Journal:  Rheumatol Int       Date:  1995       Impact factor: 2.631

3.  Kinetics of human leukocyte antigen receptor HLA-DR+ monocytes and T lymphocytes during remission induction therapy in ANCA-associated vasculitis.

Authors:  Désirée Tampe; Samy Hakroush; Lorenz Biggemann; Martin Sebastian Winkler; Björn Tampe
Journal:  J Nephrol       Date:  2022-04-21       Impact factor: 3.902

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.